[Skip to Content]
[Skip to Content Landing]
Research Letter
January 22, 2019

Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical Advertising

Author Affiliations
  • 1School of Accountancy, College of Business, Clemson University, Clemson, South Carolina
  • 2School of Accountancy, Marriott School of Business, Brigham Young University, Provo, Utah
  • 3Johns Hopkins Carey Business School, Baltimore, Maryland
  • 4Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
JAMA Intern Med. 2019;179(3):435-437. doi:10.1001/jamainternmed.2018.5976

In the “American Patients First”1 blueprint released in May 2018, the Trump administration proposed including the drug price in any direct-to-consumer pharmaceutical advertising (DTCPA) as an approach to lower prescription drug prices. In October 2018, the Centers for Medicare & Medicaid Services proposed requiring that television DTCPA disclose drug prices.2 We conducted a behavioral experiment to understand how consumers are likely to respond to the price disclosure.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×